{"log_id": 2093260600662592020, "direction": 0, "words_result_num": 41, "words_result": [{"probability": {"variance": 0.010777, "average": 0.954868, "min": 0.408553}, "location": {"width": 933, "top": 342, "height": 43, "left": 593}, "words": "00mg1210254222.3±1.08281±26289.03±3.92"}, {"probability": {"variance": 0.003029, "average": 0.978391, "min": 0.6998}, "location": {"width": 938, "top": 417, "height": 37, "left": 587}, "words": "750mg1278543422.21.16414±29469.38±3.80"}, {"probability": {"variance": 0.001556, "average": 0.983585, "min": 0.761755}, "location": {"width": 1633, "top": 483, "height": 54, "left": 279}, "words": "转移性实体瘤患者餐后单次空腹口服500mg,750mg和850mg后,吸收略有延迟,原形药"}, {"probability": {"variance": 0.010342, "average": 0.961766, "min": 0.361529}, "location": {"width": 1702, "top": 553, "height": 57, "left": 207}, "words": "物血浆浓度平均达峰时间约为395.1h,平均消除半衰期为8.5.0h。在500mg和750mg剂"}, {"probability": {"variance": 0.007442, "average": 0.963411, "min": 0.54179}, "location": {"width": 1702, "top": 625, "height": 54, "left": 207}, "words": "量组,原形药物血浆暴蹲量(AUC和Cmax)与剂量成正比例,但850mg剂量组原形药暴露量"}, {"probability": {"variance": 0.000362, "average": 0.990201, "min": 0.937019}, "location": {"width": 1074, "top": 697, "height": 51, "left": 207}, "words": "水平增加比例低于剂量增加比例。各药代动力学参数见表6"}, {"probability": {"variance": 0.010559, "average": 0.950319, "min": 0.532842}, "location": {"width": 1480, "top": 769, "height": 48, "left": 270}, "words": "表6.转移性实体瘤者单次空腹服500mg.750mg和850mg阿帕替尼后的药代动力学分析"}, {"probability": {"variance": 0, "average": 0.783924, "min": 0.783924}, "location": {"width": 28, "top": 852, "height": 28, "left": 838}, "words": "C"}, {"probability": {"variance": 0, "average": 1, "min": 1}, "location": {"width": 123, "top": 849, "height": 43, "left": 1238}, "words": " auco-sg"}, {"probability": {"variance": 0.03371, "average": 0.799738, "min": 0.616136}, "location": {"width": 270, "top": 858, "height": 201, "left": 362}, "words": "飞苏"}, {"probability": {"variance": 0.004976, "average": 0.92006, "min": 0.849523}, "location": {"width": 80, "top": 878, "height": 46, "left": 541}, "words": "剂量"}, {"probability": {"variance": 0.03122, "average": 0.897987, "min": 0.591949}, "location": {"width": 129, "top": 884, "height": 40, "left": 1010}, "words": " t-t(h)"}, {"probability": {"variance": 0.063707, "average": 0.69661, "min": 0.405966}, "location": {"width": 115, "top": 921, "height": 40, "left": 823}, "words": " np/ml)"}, {"probability": {"variance": 0.016744, "average": 0.907144, "min": 0.705094}, "location": {"width": 138, "top": 921, "height": 40, "left": 1227}, "words": " (ag.h/ml)"}, {"probability": {"variance": 0.016435, "average": 0.92265, "min": 0.433408}, "location": {"width": 613, "top": 993, "height": 40, "left": 535}, "words": "0g128406043.92±1.55"}, {"probability": {"variance": 0.008957, "average": 0.958081, "min": 0.64481}, "location": {"width": 365, "top": 993, "height": 37, "left": 1224}, "words": "5226±41558.462.49"}, {"probability": {"variance": 0.003154, "average": 0.966127, "min": 0.801156}, "location": {"width": 1062, "top": 1062, "height": 43, "left": 524}, "words": "750mg911225912.78÷0.639895+55369.07±1.29"}, {"probability": {"variance": 0.009606, "average": 0.8929, "min": 0.736813}, "location": {"width": 72, "top": 1131, "height": 34, "left": 527}, "words": "850n"}, {"probability": {"variance": 0.012403, "average": 0.947063, "min": 0.53628}, "location": {"width": 794, "top": 1131, "height": 40, "left": 792}, "words": "2528+24685.11-3.4422304±146888.99±2.06"}, {"probability": {"variance": 0.003188, "average": 0.978229, "min": 0.658336}, "location": {"width": 1618, "top": 1189, "height": 60, "left": 293}, "words": "在11例转移性实体肿瘤患者考察了750mg日多次给药的药代动力学特征。结果表明在连续"}, {"probability": {"variance": 0.005149, "average": 0.967966, "min": 0.659066}, "location": {"width": 990, "top": 1264, "height": 51, "left": 204}, "words": "给药期间(56天)、受试者体内未发生药物蓄积现象"}, {"probability": {"variance": 0.001856, "average": 0.980406, "min": 0.786343}, "location": {"width": 1575, "top": 1333, "height": 54, "left": 288}, "words": "在转移性实体瘤患者(n=9,男性6名,女性3名)中考察了进食对阿帕智尼吸收的影响"}, {"probability": {"variance": 0.005959, "average": 0.972381, "min": 0.503736}, "location": {"width": 1705, "top": 1405, "height": 54, "left": 204}, "words": "对受试者餐前1h与餐后0.5h单次口服750mg/日吸收的差异进行比较。结果表明进食与服药顺"}, {"probability": {"variance": 0.015585, "average": 0.94509, "min": 0.50249}, "location": {"width": 812, "top": 1474, "height": 48, "left": 207}, "words": "序对7max、Cmax、AUC和t均无显落影响"}, {"probability": {"variance": 0.014427, "average": 0.948736, "min": 0.450816}, "location": {"width": 1601, "top": 1540, "height": 60, "left": 288}, "words": "在转移性实体瘤志者单次口服给药的研究中观察到850mg剂量组不同性别受试者阿帕替"}, {"probability": {"variance": 0.008648, "average": 0.974973, "min": 0.386114}, "location": {"width": 1679, "top": 1612, "height": 54, "left": 207}, "words": "尼及其代谢产物M1暴露水平(Cm和AUC)存在统计学差异其中女性AUC比男性的高1.96"}, {"probability": {"variance": 0.009137, "average": 0.957461, "min": 0.479752}, "location": {"width": 1572, "top": 1684, "height": 51, "left": 207}, "words": "倍,Cmax高3.57倍。由于样本量较小(男性5例,女性4例),尚难对这种差别作出结论"}, {"probability": {"variance": 0.003148, "average": 0.983248, "min": 0.678991}, "location": {"width": 1621, "top": 1754, "height": 54, "left": 288}, "words": "年龄、体重对阿帕替尼的药代动力学特征无显著影响,因此临床使用时不需根据上述因素"}, {"probability": {"variance": 0.000344, "average": 0.990397, "min": 0.945376}, "location": {"width": 296, "top": 1826, "height": 48, "left": 207}, "words": "对剂量进行调整"}, {"probability": {"variance": 0.005426, "average": 0.963691, "min": 0.778893}, "location": {"width": 512, "top": 1889, "height": 54, "left": 290}, "words": "剂量水平与泰露平相关性"}, {"probability": {"variance": 0.001751, "average": 0.980239, "min": 0.776499}, "location": {"width": 1621, "top": 1961, "height": 54, "left": 288}, "words": "转移性实体瘤患者单次给药的药代动力学研究中,阿帕替尼的暴露水平随着口服给药剂量"}, {"probability": {"variance": 0.010466, "average": 0.952284, "min": 0.642715}, "location": {"width": 633, "top": 2033, "height": 51, "left": 207}, "words": "增加面增加,但不剂量比例关系"}, {"probability": {"variance": 0.039521, "average": 0.882545, "min": 0.538252}, "location": {"width": 169, "top": 2108, "height": 43, "left": 285}, "words": "不同瘤种"}, {"probability": {"variance": 0.013176, "average": 0.946915, "min": 0.403849}, "location": {"width": 1615, "top": 2174, "height": 48, "left": 290}, "words": "在Ⅱ期研究中分别考察了在晚期结直肠瘙患者(n=40)和晚期胃癌者(n=12)的药代动力"}, {"probability": {"variance": 0.004278, "average": 0.977156, "min": 0.590331}, "location": {"width": 1699, "top": 2240, "height": 51, "left": 207}, "words": "学特征。晚期结直肠癌患者与同等剂量下健康受试者药代参数相似,而胃癌患者吸收延迟,暴"}, {"probability": {"variance": 0.000726, "average": 0.985266, "min": 0.872032}, "location": {"width": 1699, "top": 2310, "height": 51, "left": 207}, "words": "露水平更低。晚期胃癌患者对原发病灶的手术治疗(如胃大部切除术)以及整体的体质状况可"}, {"probability": {"variance": 0.000423, "average": 0.989647, "min": 0.929442}, "location": {"width": 547, "top": 2382, "height": 51, "left": 207}, "words": "能会影响药物的的溶解和吸收"}, {"probability": {"variance": 0, "average": 0.999904, "min": 0.99986}, "location": {"width": 89, "top": 2456, "height": 46, "left": 290}, "words": "分布"}, {"probability": {"variance": 0.011136, "average": 0.964523, "min": 0.483372}, "location": {"width": 1615, "top": 2517, "height": 54, "left": 293}, "words": "健康受试者单次空腹口服250mg,500mg和750mg甲磺酸阿帕昔尼片后,平均表观分布容"}, {"probability": {"variance": 0.005493, "average": 0.959287, "min": 0.640385}, "location": {"width": 1584, "top": 2592, "height": 51, "left": 207}, "words": "积为929-2165L。用超滤法测得阿帕替尼血浆浓度在200ng/ml时的血浆蛋白结合率>86%"}, {"probability": {"variance": 0, "average": 0.999655, "min": 0.999335}, "location": {"width": 80, "top": 2667, "height": 46, "left": 296}, "words": "代谢"}], "language": -1}